604 related articles for article (PubMed ID: 25535650)
21. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set.
FitzGerald O; Helliwell P; Mease P; Mumtaz A; Coates L; Pedersen R; Nab H; Molta C
Ann Rheum Dis; 2012 Mar; 71(3):358-62. PubMed ID: 21989542
[TBL] [Abstract][Full Text] [Related]
22. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
23. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
24. Utility of the PASE questionnaire, psoriatic arthritis (PsA) prevalence and PsA improvement with anti-TNF therapy: results from the PRISTINE trial.
Husni ME; Qureshi AA; Koenig AS; Pedersen R; Robertson D
J Dermatolog Treat; 2014 Feb; 25(1):90-5. PubMed ID: 23688125
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life and disability in patients with rheumatoid, early rheumatoid and early psoriatic arthritis treated with etanercept.
Picchianti-Diamanti A; Germano V; Ferlito C; Migliore A; D'Amelio R; Laganà B
Qual Life Res; 2010 Aug; 19(6):821-6. PubMed ID: 20373036
[TBL] [Abstract][Full Text] [Related]
26. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
[TBL] [Abstract][Full Text] [Related]
27. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study.
Mazzotta A; Esposito M; Schipani C; Chimenti S
J Dermatolog Treat; 2009; 20(6):354-8. PubMed ID: 19954392
[TBL] [Abstract][Full Text] [Related]
28. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE.
Frankel EH; Strober BE; Crowley JJ; Fivenson DP; Woolley JM; Yu EB; Xia HA; Chiou CF; Stevens SR
Cutis; 2007 Apr; 79(4):322-6. PubMed ID: 17500381
[TBL] [Abstract][Full Text] [Related]
29. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.
Mease PJ; Kivitz AJ; Burch FX; Siegel EL; Cohen SB; Ory P; Salonen D; Rubenstein J; Sharp JT; Dunn M; Tsuji W
J Rheumatol; 2006 Apr; 33(4):712-21. PubMed ID: 16463435
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
31. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.
Olivieri I; Cortesi PA; de Portu S; Salvarani C; Cauli A; Lubrano E; Spadaro A; Cantini F; Ciampichini R; Cutro MS; Mathieu A; Matucci-Cerinic M; Punzi L; Scarpa R; Mantovani LG;
Clin Exp Rheumatol; 2016; 34(1):68-75. PubMed ID: 26633622
[TBL] [Abstract][Full Text] [Related]
32. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.
Mease PJ; Heckaman M; Kary S; Kupper H
J Rheumatol; 2013 May; 40(5):647-52. PubMed ID: 23504383
[TBL] [Abstract][Full Text] [Related]
33. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V
Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392
[TBL] [Abstract][Full Text] [Related]
34. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
35. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.
De Felice C; Mazzotta A; Esposito M; Bianchi L; Chimenti S
J Dermatolog Treat; 2006; 17(6):355-8. PubMed ID: 17853309
[TBL] [Abstract][Full Text] [Related]
36. Remission in psoriatic arthritis: is it possible and how can it be predicted?
Saber TP; Ng CT; Renard G; Lynch BM; Pontifex E; Walsh CA; Grier A; Molloy M; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
Arthritis Res Ther; 2010; 12(3):R94. PubMed ID: 20482783
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Health Outcomes with Etanercept Treatment in Patients with Early Nonradiographic Axial Spondyloarthritis.
Dougados M; Tsai WC; Saaibi DL; Bonin R; Bukowski J; Pedersen R; Vlahos B; Kotak S
J Rheumatol; 2015 Oct; 42(10):1835-41. PubMed ID: 26276968
[TBL] [Abstract][Full Text] [Related]
38. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
Mease PJ; Goffe BS; Metz J; VanderStoep A; Finck B; Burge DJ
Lancet; 2000 Jul; 356(9227):385-90. PubMed ID: 10972371
[TBL] [Abstract][Full Text] [Related]
39. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study.
Gottlieb AB; Kircik L; Eisen D; Jackson JM; Boh EE; Strober BE; Frankel E; Xia HA; Stevens SR
J Dermatolog Treat; 2006; 17(6):343-52. PubMed ID: 17853307
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey.
Brodszky V; Péntek M; Bálint PV; Géher P; Hajdu O; Hodinka L; Horváth G; Koó E; Polgár A; Seszták M; Szántó S; Ujfalussy I; Gulácsi L
Scand J Rheumatol; 2010 Aug; 39(4):303-9. PubMed ID: 20166848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
